Back to results
US 12,319,936 B2Granted
Natural killer cells exhibiting increased anticancer activity and immunotherapeutic use thereof
AssigneesCha Biotech Co., Ltd., Cha Biolab Co., Ltd.
InventorsYoung Seok Baek, In Jee Lee
Life of this patent
Estimating the term…
Abstract
Provided are a natural killer cell exhibiting increased anticancer activity and immunotherapeutic use thereof. According to the natural killer cell according to an aspect, a relative mean fluorescence intensity (MFI) of a specific receptor significant for cancers including glioblastoma is increased, and thus effective anticancer immunotherapy is possible.
Claims12
A method of treating cancer, the method comprising administering an effective amount of an isolated natural killer cell, wherein the natural killer cell has:
- (1) an expression level of a KIR2DS4 gene on day 14 of culture which is 10 times to 50 times higher compared with that on day 0 of peripheral blood mononuclear cell (PBMC) culture;
- and
- (2) one or more characteristics selected from the following (a) to (e) or a population thereof to an individual in need thereof:
- (a) a relative mean fluorescence intensity (MFI) value of NKG2D exhibits a 1.2-fold to 12-fold increase, as compared with that on day 0 of PBMC culture;
- (b) a relative MFI value of NKp30 exhibits a 1.5-fold to 15-fold increase, as compared with that on day 0 of PBMC culture;
- (c) a relative MFI value of NKp44 exhibits a 12-fold to 22-fold increase, as compared with that on day 0 of PBMC culture;
- (d) a relative MFI value of integrin subunit alpha 1 (ITGA1) exhibits a 1.8-fold to 25-fold increase, as compared with that on day 0 of PBMC culture;
- and
- (e) a relative MFI value of integrin subunit alpha 2 (ITGA2) exhibits a 1.4-fold to 6-fold increase, as compared with that on day 0 of PBMC culture;
- wherein the relative MFI is defined by the following Equation 1:
- Relative MFI=Receptor MFI/Isotype MFI. [Equation 1]
8 more elements
Dependencies are inferred from the claim text.